Transcatheter Arterial Chemotherapy with Miriplatin for Hepatocellular Carcinoma Patients with Chronic Renal Failure: Report of Three Cases
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Miriplatin is a novel lipophilic platinum complex that was developed to treat hepatocellular carcinoma (HCC). Although HCC patients frequently have coexisting chronic renal failure,little prospective data are available regarding the clinical toxicity of chemotherapeutic agents used to treat HCC patients with chronic renal failure. In a phase II study, the plasma concentration of total platinum in patients who received miriplatin was very low, and no severe renal toxicity caused by miriplatin injection was reported. Here, we present three cases of HCC with stage 4 chronic renal failure who received transcatheter arterial chemotherapy with miriplatin. All cases were male, ages 72, 84, and 83 years, and had serum creatinine levels of 2.3, 1.6, and 1.9 mg/dL, respectively. Their estimated glomerular filtration rates were 21.9, 20.3, and 22.2 mL/min, respectively. All cases were treated for unresectable HCC with transcatheter arterial chemotherapy with miriplatin. No serious adverse events were observed, and serum creatinine levels did not elevate, even in the patient who experienced renal failure caused by cisplatin administration. These results might suggest that transcatheter arterial chemotherapy with miriplatin can be safely used in HCC patients with chronic renal failure
Abstract
Miriplatin is a novel lipophilic platinum complex that was developed to treat hepatocellular carcinoma (HCC). Although HCC patients frequently have coexisting chronic renal failure,little prospective data are available regarding the clinical toxicity of chemotherapeutic agents used to treat HCC patients with chronic renal failure. In a phase II study, the plasma concentration of total platinum in patients who received miriplatin was very low, and no severe renal toxicity caused by miriplatin injection was reported. Here, we present three cases of HCC with stage 4 chronic renal failure who received transcatheter arterial chemotherapy with miriplatin. All cases were male, ages 72, 84, and 83 years, and had serum creatinine levels of 2.3, 1.6, and 1.9 mg/dL, respectively. Their estimated glomerular filtration rates were 21.9, 20.3, and 22.2 mL/min, respectively. All cases were treated for unresectable HCC with transcatheter arterial chemotherapy with miriplatin. No serious adverse events were observed, and serum creatinine levels did not elevate, even in the patient who experienced renal failure caused by cisplatin administration. These results might suggest that transcatheter arterial chemotherapy with miriplatin can be safely used in HCC patients with chronic renal failure
참고문헌 (23)
- Parkin DM, "Global cancer statistics, 2002", CA Cancer J Clin, 55, pp.74~108 (2005)
- Kamada K, "Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion", J Vasc Interv Radiol, 12, pp.847~854 (2001)
- Camma C, "Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials", Radiology, 224, pp.47~54 (2002)
- Ikeda M, "Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma", Oncology, 66, pp.24~31 (2004)
- Takayasu K, "Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients", Gastroenterology, 131, pp.461~469 (2006)
- Marelli L, "Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies", Cardiovasc Intervent Radiol, 30, pp.6~25 (2007)
- Ikeda M, "Transcatheter arterial infusion chemotherapy with cisplatin-lipiodol suspension in patients with hepatocellular carcinoma", J Gastroenterol, 45, pp.60~67 (2010)
- Laragh JH, "Angiotensin Ii, Norepinephrine, and renal transport of electrolytes and water in normal man and in cirrhosis with ascites", J Clin Invest, 42, pp.1179~1192 (1963)
- Cardenas A, "Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis", Hepatology, 34(4 Pt 1), pp.671~676 (2001)
- Moreau R, "Acute renal failure in patients with cirrhosis: perspectives in the age of MELD", Hepatology, 37, pp.233~243 (2003)
- Huo TI, "Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study", Liver Int, 24, pp.210~215 (2004)
- Huo TI, "Acute renal failure after transarterial chemoembolization for hepatocellular carcinoma: a retrospective study of the incidence, risk factors, clinical course and long-term outcome", Aliment Pharmacol Ther, 19, pp.999~1007 (2004)
- Hsu CY, "Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization", Liver Int, 30, pp.77~84 (2010)
- Maeda M, "Liposoluble platinum(II) complexes with antitumor activity", Jpn J Cancer Res, 77, pp.523~525 (1986)
- platinum(II) suspended in Lipiodol, "Biol Pharm Bull", 2003, 683~686
- Fujiyama S, "Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma refractory to cisplatin", lipiodol, 2003, pp.89, 1614~1619
- Okusaka T, "Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma", Invest New Drugs, 22, pp.169~176 (2004)
- Hanada M, "Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of human hepatoma cells orthotopically implanted in nude rats", Cancer Sci, 100, pp.189~194 (2009)
- Hanada M, "Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis", Cancer Chemother Pharmacol, 64, pp.473~483 (2009)
- "K", DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative, 2002, pp.39(Suppl 2), S7~S245
- Matsuo S, "Revised equations for estimated GFR from serum creatinine in Japan", Am J Kidney Dis, 53, pp.982~992 (2009)
- Lencioni R, "Modified RECIST (mRECIST) assessment for hepatocellular carcinoma", Semin Liver Dis, 30, pp.52~60 (2010)
- Kawamura Y, "Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin", Hepatol Res, 39, pp.346~354 (2009)